New Two-Drug combo aims to tame chronic hepatitis b

NCT ID NCT05276297

Completed Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed phase 2 study tested a two-step treatment for chronic hepatitis B. First, participants received an antisense drug (bepirovirsen) for 12 or 24 weeks, followed by a targeted immunotherapy. The goal was to see if this sequence could safely improve virus control beyond standard antiviral therapy alone. The trial involved 174 adults aged 18-65 who were already stable on antiviral medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Bepirovirsen (GSK3228836) and a hepatitis B targeted immunotherapy (GSK3528869A)
What this could lead to: If successful, this sequential approach could help more people with chronic hepatitis B achieve long-term control of the virus without needing lifelong medication.
What could go wrong: This is a phase 2 trial with only 174 participants, so results are preliminary. The treatment involves two different drugs with potential side effects like liver inflammation and blood disorders.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS B CHRONIC

Contacts and locations

Locations

GSK Investigational Site

Edegem, 2650, Belgium
GSK Investigational Site

Sliven, 8800, Bulgaria
GSK Investigational Site

Sofia, 1407, Bulgaria
GSK Investigational Site

Sofia, 1431, Bulgaria
GSK Investigational Site

Sofia, 1784, Bulgaria
GSK Investigational Site

Sofia, 1797, Bulgaria
GSK Investigational Site

Veliko Tarnovo, 5000, Bulgaria
GSK Investigational Site

Vratsa, 3000, Bulgaria
GSK Investigational Site

Clichy, 92118, France
GSK Investigational Site

Créteil, 94010, France
GSK Investigational Site

Lyon, 69317, France
GSK Investigational Site

Strasbourg, 67091, France
GSK Investigational Site

Berlin, 10787, Germany
GSK Investigational Site

Frankfurt, 60590, Germany
GSK Investigational Site

Leipzig, 04103, Germany
GSK Investigational Site

Pokfulam, Hong Kong
GSK Investigational Site

Bergamo, Italy
GSK Investigational Site

Milan, 20122, Italy
GSK Investigational Site

Milan, 20157, Italy
GSK Investigational Site

Roma, 00133, Italy
GSK Investigational Site

Rozzano MI, 20089, Italy
GSK Investigational Site

Makati City, 1229, Philippines
GSK Investigational Site

Pasig, 1605, Philippines
GSK Investigational Site

Krakow, 31-202, Poland
GSK Investigational Site

Mysłowice, 41-400, Poland
GSK Investigational Site

Łańcut, 37-100, Poland
GSK Investigational Site

Cluj-Napoca, 400162, Romania
GSK Investigational Site

Craiova Dolj, 200515, Romania
GSK Investigational Site

Singapore, 119074, Singapore
GSK Investigational Site

Singapore, 169608, Singapore
GSK Investigational Site

Barcelona, 08011, Spain
GSK Investigational Site

Madrid, 28006, Spain
GSK Investigational Site

Madrid, 28007, Spain
GSK Investigational Site

Madrid, 28034, Spain
GSK Investigational Site

Madrid, 28046, Spain
GSK Investigational Site

Madrid, 28222, Spain
GSK Investigational Site

Santander, 39008, Spain
GSK Investigational Site

Seville, 41013, Spain
GSK Investigational Site

Vigo, 36071, Spain
GSK Investigational Site

Chiayi City, 600, Taiwan
GSK Investigational Site

Kaohsiung City, 807, Taiwan
GSK Investigational Site

Linkou - Taoyuan Hsien, 333, Taiwan
GSK Investigational Site

Taichung, 404, Taiwan
GSK Investigational Site

Taichung, 40705, Taiwan
GSK Investigational Site

Tainan, 704, Taiwan
GSK Investigational Site

Bangkok, 10330, Thailand
GSK Investigational Site

Chiang Mai, 50200, Thailand
GSK Investigational Site

Istanbul, 6690, Turkey (Türkiye)
GSK Investigational Site

Rize, 53200, Turkey (Türkiye)
GSK Investigational Site

Cottingham, HU16 5JQ, United Kingdom
GSK Investigational Site

Leicester, LE1 5WW, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.